시장보고서
상품코드
1150068

세계의 파킨슨병 치료 시장 : 점유율, 규모, 동향, 업계 분석 - 약제 클래스별, 유통 채널별, 투여 경로별, 환자 케어 환경별, 지역별, 부문 예측(2022-2030년)

Parkinson´s Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class ; By Distribution Channel; By Route of Administration; By Patient Care Setting; By Region; Segment Forecast, 2022 - 2030

발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 115 Pages | 배송안내 : 1-2일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 파킨슨병 치료 시장 규모는 2030년까지 77억 4,000만 달러에 달할 것으로 예측됩니다.

세계의 파킨슨병 치료(Parkinson's Disease Treatment) 시장에 대해 조사했으며, 시장 역학, 부문별 분석, 지역 분석, 기업 개요 등의 정보를 제공하고 있습니다.

목차

제1장 서론

  • 보고서 설명
    • 조사 목적
    • 시장 범위
    • 가정
  • 이해관계자

제2장 주요 요약

  • 시장 하이라이트

제3장 조사 방법

  • 개요
    • 데이터 마이닝
  • 정보 출처
    • 1차 정보
    • 2차 정보

제4장 세계의 파킨슨병 치료 시장 인사이트

  • 파킨슨병 치료 - 업계 현황
  • 파킨슨병 치료 시장 역학
    • 성장 촉진요인과 기회
    • 성장 억제요인과 과제
  • Porter's Five Forces 분석
    • 공급 기업의 협상력
    • 신규 참여업체의 위협
    • 구매자의 협상력
    • 대체품의 위협
    • 기존 기업간 경쟁력
  • PESTLE 분석
  • 파킨슨병 치료 업계 동향
  • 밸류체인 분석
  • COVID-19 영향 분석

제5장 세계의 파킨슨병 치료 시장 : 약제 클래스별

  • 주요 조사 결과
  • 서론
    • 세계의 파킨슨병 치료 시장 : 약제 클래스별(2018-2030년)
  • 레보도파/카르비도파
    • 세계의 파킨슨병 치료 시장 : 레보도파/카르비도파별, 지역별(2018-2030년)
  • 도파민 수용체 작용제
    • 세계의 파킨슨병 치료 시장 : 도파민 수용체 작용제별, 지역별(2018-2030년)
  • MAO 억제제
    • 세계의 파킨슨병 치료 시장 : MAO 억제제별, 지역별(2018-2030년)
  • COMT 억제제
    • 세계의 파킨슨병 치료 시장 : COMT 억제제별, 지역별(2018-2030년)
  • 항콜린제
    • 세계의 파킨슨병 치료 시장 : 항콜린제별, 지역별(2018-2030년)
  • 기타 약제
    • 세계의 파킨슨병 치료 시장 : 기타 약제별, 지역별(2018-2030년)

제6장 세계의 파킨슨병 치료 시장 : 유통 채널별

  • 주요 조사 결과
  • 서론
    • 세계의 파킨슨병 치료 시장 : 유통 채널별(2018-2030년)
  • 병원 약국
    • 세계의 파킨슨병 치료 시장 : 병원 약국별, 지역별(2018-2030년)
  • 소매 약국
    • 세계의 파킨슨병 치료 시장 : 소매 약국별, 지역별(2018-2030년)
  • 온라인 약국
    • 세계의 파킨슨병 치료 시장 : 온라인 약국별, 지역별(2018-2030년)

제7장 세계의 파킨슨병 치료 시장 : 투여 경로별

  • 주요 조사 결과
  • 서론
    • 세계의 파킨슨병 치료 시장 : 투여 경로별(2018-2030년)
  • 경구
    • 세계의 파킨슨병 치료 시장 : 경구별, 지역별(2018-2030년)
  • 피하
    • 세계의 파킨슨병 치료 시장 : 피하별, 지역별(2018-2030년)
  • 경피
    • 세계의 파킨슨병 치료 시장 : 경피별, 지역별(2018-2030년)
  • 기타
    • 세계의 파킨슨병 치료 시장 : 기타 투여 경로별, 지역별(2018-2030년)

제8장 세계의 파킨슨병 치료 시장 : 환자 케어 환경별

  • 주요 조사 결과
  • 서론
    • 세계의 파킨슨병 치료 시장 : 환자 케어 환경별(2018-2030년)
  • 진료소
    • 세계의 파킨슨병 치료 시장 : 진료소별, 지역별(2018-2030년)
  • 병원
    • 세계의 파킨슨병 치료 시장 : 병원별, 지역별(2018-2030년)

제9장 세계의 파킨슨병 치료 시장 : 지역별

  • 주요 조사 결과
  • 서론
    • 파킨슨병 치료 시장 평가 : 지역별(2018-2030년)
  • 북미
    • 약제 클래스별(2018-2030년)
    • 환자 케어 환경별(2018-2030년)
    • 유통 채널별(2018-2030년)
    • 투여 경로별(2018-2030년)
    • 미국
    • 캐나다
  • 유럽
    • 약제 클래스별(2018-2030년)
    • 환자 케어 환경별(2018-2030년)
    • 유통 채널별(2018-2030년)
    • 투여 경로별(2018-2030년)
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
  • 아시아태평양
    • 약제 클래스별(2018-2030년)
    • 환자 케어 환경별(2018-2030년)
    • 유통 채널별(2018-2030년)
    • 투여 경로별(2018-2030년)
    • 중국
    • 인도
    • 일본
    • 말레이시아
    • 인도네시아
    • 한국
  • 중동 및 아프리카
    • 약제 클래스별(2018-2030년)
    • 환자 케어 환경별(2018-2030년)
    • 유통 채널별(2018-2030년)
    • 투여 경로별(2018-2030년)
    • 사우디아라비아
    • 남아프리카공화국
    • 이스라엘
    • 아랍에미리트
  • 라틴아메리카
    • 약제 클래스별(2018-2030년)
    • 환자 케어 환경별(2018-2030년)
    • 유통 채널별(2018-2030년)
    • 투여 경로별(2018-2030년)
    • 멕시코
    • 브라질
    • 아르헨티나

제10장 경쟁 상황

  • 사업 확대와 인수 분석
    • 사업 확대
    • 인수
  • 파트너십/협업/협정/전시회

제11장 기업 개요

  • Abbvie Inc
  • Acadia Pharmaceuticals Inc
  • Apotex Inc
  • Axovant Gene Therapies Ltd
  • Boehringer Ingelheim GmbH
  • Bausch Health Companies Inc
  • Boston Scientific Corp
  • Cipla Inc
  • Daiichi Sankyo Espha Co., Ltd.
  • Eli Lilly & Co
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline Plc
  • Impax Laboratories, Inc
  • Merck & Company
  • Mylan Nv
  • Novartis AG
  • Pfizer Incorporation
  • Sanofi Sa
  • Teva Pharmaceutical Industries Ltd
  • Vertical Pharmaceuticals, Llc
  • And Wockhardt Ltd.
KSM 22.11.25

The global Parkinson's disease treatment market size is expected to reach USD 7.74 billion by 2030, according to a new study by Polaris Market Research. The report "Parkinson's Disease Treatment Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Levodopa/carbidopa, Dopamine Receptor Agonists, MAO-Inhibitors, COMT-inhibitors, Anticholinergics, and Other Drugs); By Distribution Channel; By Route of Administration; By Patient Care Setting; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Parkinson's disease is becoming more common, which has prompted the creation of potent treatments for the condition. Regulating bodies, such as the U.S. Food and Drug Administration, is in charge of managing these. For instance, Levodopa/carbidopa patients encounter "off" episodes when taking the medication. To combat the side effects of levodopa/carbidopa in adult Parkinson's disease patients, the FDA-approved drugs. In August 2019, as a supplement to levodopa/carbidopa in adult Parkinson's disease (PD) patients who are having "off" episodes, the U.S. Food and Drug Administration approved Nourianz (istradefylline) tablets. PD symptoms, such as trembling and difficulty walking, might worsen during an "off" episode when a patient's treatments are not working as intended. The European Medicines Agency oversees the European licensing process for medications used to treat Parkinson's disease.

Growing investment in R&D will result in the creation of innovative treatments, which will further aid in industry expansion. According to Parkinson's Foundation, it has invested around USD around 4.5 million in innovative projects. Also, as per the National Institute of Health, of the $242 million in NIH funding for PD research in the financial year 2020, over $130 million was provided by the NINDS. In addition, in 2021, around $249 million was invested in innovative research to treat Parkinson's disease.

Furtherly, the growth in the aging population and the associated increase in the prevalence of Parkinson's disease are primary reasons driving the global market revenue. In addition, a robust new drug development pipeline is a significant trend that strengthens the industry's growth.

Moreover, in November 2021, the Aligning Science Across Parkinson's (ASAP) Collaborative Research Network awarded Emory Academic researchers a three-year, $6.3 million grant to study the behavioral cortical abnormalities brought on by Parkinson's disease (PD). The need for this disease treatment will increase public awareness of successful treatments.

Parkinson's Disease Treatment Market Report Highlights

COMT-inhibitors are anticipated to grow at the highest CAGR over the forecast period. Levodopa (LD) therapy has been shown to benefit from the addition of COMT inhibitors since they enhance LD bioavailability and prolonged LD elimination in Parkinson's patients. To increase their use and demand, COMT inhibitors must demonstrate their benefits.

Hospital segment records significant revenue share because therapy and treatments can be delivered on-site. Reducing the necessity for pharmacy visits and increasing the use of hospital settings.

Asia-Pacific is expected to hold the fastest CAGR over the forecast period. This is expanding due to increased healthcare organizations and Parkinson's disease prevalence. Additionally, the region's growing senior population impacts the market for these disease treatments.

The global market is highly competitive owing to large market players with a global presence, including Abbvie Incorporation., Boston Scientific Corporation., Eli Lilly & Co., F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Novartis AG, Pfizer Inc., and Wockhardt Ltd.

Polaris Market Research has segmented the Parkinson's Disease Treatment market report based on drug class, distribution channel, route of administration, patient care setting, and region:

Parkinson's Disease Treatment, Drug Class Outlook (Revenue - USD Billion, 2018 - 2030)

Levodopa/carbidopa

Dopamine Receptor Agonists

MAO-Inhibitors

COMT-inhibitors

Anticholinergics

Other Drugs

Parkinson's Disease Treatment, Distribution Channel Outlook (Revenue - USD Billion, 2018 - 2030)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Parkinson's Disease Treatment, Route of Administration Setting Outlook (Revenue - USD Billion, 2018 - 2030)

Oral

Subcutaneous

Transdermal

Others

Parkinson's Disease Treatment, Patient Care Setting Outlook (Revenue - USD Billion, 2018 - 2030)

Clinics

Hospitals

Parkinson's Disease Treatment, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Parkinson's Disease Treatment Market Insights

  • 4.1. Parkinson's Disease Treatment - Industry Snapshot
  • 4.2. Parkinson's Disease Treatment Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Grow in aging population and the associated increase in the prevalence in parkinson's disease
      • 4.2.1.2. Government funding for research
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Availability of alternative treatments
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Parkinson's Disease Treatment Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Parkinson's Disease Treatment Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
  • 5.3. Levodopa/carbidopa
    • 5.3.1. Global Parkinson's Disease Treatment Market, by Levodopa/carbidopa, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Dopamine Receptor Agonists
    • 5.4.1. Global Parkinson's Disease Treatment Market, by Dopamine Receptor Agonists, by Region, 2018 - 2030 (USD Billion)
  • 5.5. MAO-Inhibitors
    • 5.5.1. Global Parkinson's Disease Treatment Market, by MAO-Inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 5.6. COMT-inhibitors
    • 5.6.1. Global Parkinson's Disease Treatment Market, by COMT-inhibitors, by Region, 2018 - 2030 (USD Billion)
  • 5.7. Anticholinergics
    • 5.7.1. Global Parkinson's Disease Treatment Market, by Anticholinergics, by Region, 2018 - 2030 (USD Billion)
  • 5.8. Other Drugs
    • 5.8.1. Global Parkinson's Disease Treatment Market, by Other Drugs, by Region, 2018 - 2030 (USD Billion)

6. Global Parkinson's Disease Treatment Market, by Distribution Channel

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Global Parkinson's Disease Treatment Market, by Hospital Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Retail Pharmacies
    • 6.4.1. Global Parkinson's Disease Treatment Market, by Retail Pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Online Pharmacies
    • 6.5.1. Global Parkinson's Disease Treatment Market, by Online Pharmacies, by Region, 2018 - 2030 (USD Billion)

7. Global Parkinson's Disease Treatment Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 7.3. Oral
    • 7.3.1. Global Parkinson's Disease Treatment Market, by Oral, by Region, 2018 - 2030 (USD Billion)
  • 7.4. Subcutaneous
    • 7.4.1. Global Parkinson's Disease Treatment Market, by Subcutaneous, by Region, 2018 - 2030 (USD Billion)
  • 7.5. Transdermal
    • 7.5.1. Global Parkinson's Disease Treatment Market, by Transdermal, by Region, 2018 - 2030 (USD Billion)
  • 7.6. Others
    • 7.6.1. Global Other Parkinson's Disease Treatment Market, by Region, 2018 - 2030 (USD Billion)

8. Global Parkinson's Disease Treatment Market, by Patient Care Setting

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
  • 8.3. Clinics
    • 8.3.1. Global Parkinson's Disease Treatment Market, by Clinics, by Region, 2018 - 2030 (USD Billion)
  • 8.4. Hospitals
    • 8.4.1. Global Parkinson's Disease Treatment Market, by Hospitals, by Region, 2018 - 2030 (USD Billion)

9. Global Parkinson's Disease Treatment Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Parkinson's Disease Treatment Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 9.3. Parkinson's Disease Treatment Market - North America
    • 9.3.1. North America: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 9.3.2. North America: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
    • 9.3.3. North America: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.3.4. North America: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.3.5. Parkinson's Disease Treatment Market - U.S.
      • 9.3.5.1. U.S.: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.3.5.2. U.S.: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.3.5.3. U.S.: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.3.5.4. U.S.: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.3.6. Parkinson's Disease Treatment Market - Canada
      • 9.3.6.1. Canada: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.3.6.2. Canada: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.3.6.3. Canada: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.3.6.4. Canada: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.4. Parkinson's Disease Treatment Market - Europe
    • 9.4.1. Europe: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 9.4.2. Europe: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
    • 9.4.3. Europe: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.4.4. Europe: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.5. Parkinson's Disease Treatment Market - UK
      • 9.4.5.1. UK: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.4.5.2. UK: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.4.5.3. UK: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.5.4. UK: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.6. Parkinson's Disease Treatment Market - France
      • 9.4.6.1. France: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.4.6.2. France: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.4.6.3. France: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.6.4. France: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.7. Parkinson's Disease Treatment Market - Germany
      • 9.4.7.1. Germany: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.4.7.2. Germany: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.4.7.3. Germany: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.7.4. Germany: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.8. Parkinson's Disease Treatment Market - Italy
      • 9.4.8.1. Italy: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.4.8.2. Italy: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.4.8.3. Italy: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.8.4. Italy: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.9. Parkinson's Disease Treatment Market - Spain
      • 9.4.9.1. Spain: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.4.9.2. Spain: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.4.9.3. Spain: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.9.4. Spain: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.10. Parkinson's Disease Treatment Market - Netherlands
      • 9.4.10.1. Netherlands: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.4.10.2. Netherlands: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.4.10.3. Netherlands: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.10.4. Netherlands: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.11. Parkinson's Disease Treatment Market - Russia
      • 9.4.11.1. Russia: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.4.11.2. Russia.: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.4.11.3. Russia: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.4.11.4. Russia: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.5. Parkinson's Disease Treatment Market - Asia Pacific
    • 9.5.1. Asia Pacific: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 9.5.2. Asia Pacific: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
    • 9.5.3. Asia Pacific: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.5.4. Asia Pacific: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.5. Parkinson's Disease Treatment Market - China
      • 9.5.5.1. China: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.5.5.2. China.: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.5.5.3. China: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.5.4. China: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.6. Parkinson's Disease Treatment Market - India
      • 9.5.6.1. India: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.5.6.2. India.: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.5.6.3. India: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.6.4. India: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.7. Parkinson's Disease Treatment Market - Japan
      • 9.5.7.1. Japan: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.5.7.2. Japan.: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.5.7.3. Japan: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.7.4. Japan: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.8. Parkinson's Disease Treatment Market - Malaysia
      • 9.5.8.1. Malaysia: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.5.8.2. Malaysia.: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.5.8.3. Malaysia: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.8.4. Malaysia: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.9. Parkinson's Disease Treatment Market - Indonesia
      • 9.5.9.1. Indonesia: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.5.9.2. Indonesia.: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.5.9.3. Indonesia: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.9.4. Indonesia: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.10. Parkinson's Disease Treatment Market - South Korea
      • 9.5.10.1. South Korea: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.5.10.2. South Korea.: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.5.10.3. South Korea: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.5.10.4. South Korea: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.6. Parkinson's Disease Treatment Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 9.6.2. Middle East & Africa: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
    • 9.6.3. Middle East & Africa: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.6.4. Middle East & Africa: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.5. Parkinson's Disease Treatment Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.6. Parkinson's Disease Treatment Market - South Africa
      • 9.6.6.1. South Africa: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.6.6.2. South Africa: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.6.6.3. South Africa: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.6.6.4. South Africa: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.7. Parkinson's Disease Treatment Market - Israel
      • 9.6.7.1. Israel: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.6.7.2. Israel: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.6.7.3. Israel: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.6.7.4. Israel: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.8. Parkinson's Disease Treatment Market - UAE
      • 9.6.8.1. UAE: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.6.8.2. UAE: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.6.8.3. UAE: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.6.8.4. UAE: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.7. Parkinson's Disease Treatment Market - Latin America
    • 9.7.1. Latin America: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
    • 9.7.2. Latin America: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
    • 9.7.3. Latin America: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.7.4. Latin America: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.7.5. Parkinson's Disease Treatment Market - Mexico
      • 9.7.5.1. Mexico: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.7.5.2. Mexico: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.7.5.3. Mexico: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.7.5.4. Mexico: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.7.6. Parkinson's Disease Treatment Market - Brazil
      • 9.7.6.1. Brazil: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.7.6.2. Brazil: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.7.6.3. Brazil: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.7.6.4. Brazil: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.7.7. Parkinson's Disease Treatment Market - Argentina
      • 9.7.7.1. Argentina: Parkinson's Disease Treatment Market, by Drug Class, 2018 - 2030 (USD Billion)
      • 9.7.7.2. Argentina: Parkinson's Disease Treatment Market, by Patient Care Setting, 2018 - 2030 (USD Billion)
      • 9.7.7.3. Argentina: Parkinson's Disease Treatment Market, by Distribution Channel, 2018 - 2030 (USD Billion)
      • 9.7.7.4. Argentina: Parkinson's Disease Treatment Market, by Route of Administration, 2018 - 2030 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Abbvie Inc
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Acadia Pharmaceuticals Inc
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Apotex Inc
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Axovant Gene Therapies Ltd
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Boehringer Ingelheim GmbH
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Bausch Health Companies Inc
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Boston Scientific Corp
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Cipla Inc
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Daiichi Sankyo Espha Co., Ltd.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Eli Lilly & Co
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Eisai Co., Ltd.
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. F. Hoffmann-La Roche AG
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development
  • 11.13. GlaxoSmithKline Plc
    • 11.13.1. Company Overview
    • 11.13.2. Financial Performance
    • 11.13.3. Product Benchmarking
    • 11.13.4. Recent Development
  • 11.14. Impax Laboratories, Inc
    • 11.14.1. Company Overview
    • 11.14.2. Financial Performance
    • 11.14.3. Product Benchmarking
    • 11.14.4. Recent Development
  • 11.15. Merck & Company
    • 11.15.1. Company Overview
    • 11.15.2. Financial Performance
    • 11.15.3. Product Benchmarking
    • 11.15.4. Recent Development
  • 11.16. Mylan Nv
    • 11.16.1. Company Overview
    • 11.16.2. Financial Performance
    • 11.16.3. Product Benchmarking
    • 11.16.4. Recent Development
  • 11.17. Novartis AG
    • 11.17.1. Company Overview
    • 11.17.2. Financial Performance
    • 11.17.3. Product Benchmarking
    • 11.17.4. Recent Development
  • 11.18. Pfizer Incorporation
    • 11.18.1. Company Overview
    • 11.18.2. Financial Performance
    • 11.18.3. Product Benchmarking
    • 11.18.4. Recent Development
  • 11.19. Sanofi Sa
    • 11.19.1. Company Overview
    • 11.19.2. Financial Performance
    • 11.19.3. Product Benchmarking
    • 11.19.4. Recent Development
  • 11.20. Teva Pharmaceutical Industries Ltd
    • 11.20.1. Company Overview
    • 11.20.2. Financial Performance
    • 11.20.3. Product Benchmarking
    • 11.20.4. Recent Development
  • 11.21. Vertical Pharmaceuticals, Llc
    • 11.21.1. Company Overview
    • 11.21.2. Financial Performance
    • 11.21.3. Product Benchmarking
    • 11.21.4. Recent Development
  • 11.22. And Wockhardt Ltd.
    • 11.22.1. Company Overview
    • 11.22.2. Financial Performance
    • 11.22.3. Product Benchmarking
    • 11.22.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제